Nano-X Imaging Ltd., a development-stage company, develops, produces, and commercializes digital X-ray source technology for the medical imaging industry worldwide. Its X-ray source is based on a novel digital MEMs semiconductor cathode. The company also develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. Nano-X Imaging Ltd. was founded in 2011 and is headquartered in Neve Ilan, Israel.
IPO Year: 2020
Exchange: NASDAQ
Website: nanox.vision
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2025 | $23.00 | Buy | D. Boral Capital |
| 9/8/2023 | $14.50 | Buy | Alliance Global Partners |
| 1/5/2023 | $21.00 | Overweight | Cantor Fitzgerald |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Nano-X Imaging Ltd. (0001795251) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00
Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50
Cantor Fitzgerald initiated coverage of Nano-X Imaging with a rating of Overweight and set a new price target of $21.00
Ladenburg Thalmann initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $52.00
Cantor Fitzgerald reiterated coverage of Nano X Imaging with a rating of Overweight and set a new price target of $67.00 from $70.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
4 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
SCHEDULE 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
20-F - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
EFFECT - Nano-X Imaging Ltd. (0001795251) (Filer)
F-3/A - Nano-X Imaging Ltd. (0001795251) (Filer)
F-3 - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
424B5 - Nano-X Imaging Ltd. (0001795251) (Filer)
Fastest customizable press release news feed in the world
Initial deployment is expected to include six Nanox.ARC systems under a capex model PETACH TIKVA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (("Nanox", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement with Top Med SAC ("Top Med") to deploy the Nanox.ARC system and related services in Peru. Under the agreement, Nanox appointed Top Med as its exclusive distributor of the Nanox.ARC system and Nanox platform in Peru, subject to commercial milestones and regulatory requirements. The agreement is structured as a capex model and includes an expected initial deployment of six Nanox.ARC systems, subject to receipt of t
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifyi
Advances Nanox's ongoing U.S. commercialization and deployment efforts PETACH TIKVA, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Nano X Imaging Ltd. (("Nanox", or the "Company", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a distribution agreement with NuvioDx LLC ("NuvioDx"), an imaging solutions provider focused on expanding access to diagnostic imaging, to support the deployment of Nanox.ARC systems. This agreement represents Nanox's growing distribution framework announced in 2026, following recent agreements, as the company continues to advance its channel partner strategy and build a dive
Expands Nanox's growing network of U.S. distribution partnerships PETAH TIKVA, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (("Nanox", or the "Company", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a distribution agreement with Radiology Oncology Systems, a U.S. provider of diagnostic imaging and oncology equipment solutions serving hospitals and clinics nationwide, to distribute its Nanox.ARC systems across the U.S. Under the terms of the agreement, Radiology Oncology Systems will support the commercial rollout of the Nanox.ARC, an FDA-cleared, multisource digital tomosynt
Howard's nationwide reach across healthcare and public sector markets expands Nanox's U.S. channel partner network to additional customer segments PETAH TIKVA, Israel, April 20, 2026 -- Nano-X Imaging Ltd. (("Nanox", or the "Company", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced a strategic commercial agreement with Howard Technology Solutions, a leading U.S.-based technology solutions provider with deep expertise in healthcare and a broad national footprint. The agreement will support the commercial rollout of the Nanox.ARC, an FDA-cleared, multisource digital tomosynthesis system that makes 3D imaging possible in more clinical settings, at a lower cost
Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI Management to host conference call and webcast Monday, April 20, 2026 at 8:30 AM ET Appointed new CFO effective August 1, 2026 PETAH TIKVA, Israel, April 20, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2025, and provided a business update. Recent Highlights: Generated $3.7 million in revenue in the fourth quarter of 2025, compared to $3.0 million in the fourth quarter o
Enhancing emergency triage imaging with Nanox.ARC to improve efficiency and lower radiation dose Collaboration expands clinical evidence base of Nanox.ARC to support broader adoption PETACH TIKVA, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (("Nanox", or the "Company", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced a clinical collaboration with Meir Medical Center, part of the Clalit Health Services, Israel's largest healthcare organization, aimed at enhancing and expanding the established clinical validation of the Nanox.ARC. The clinical study is designed to demonstrate the diagnostic value of the Nanox.ARC system for orthopedic inj
Fourth distribution agreement of 2026 strengthens Nanox's U.S. commercial momentum PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- Nano X Imaging Ltd. (NASDAQ NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a new distribution agreement with Digital X-Ray Imaging Inc., a leading diagnostic imaging provider serving healthcare facilities across Arkansas. The agreement will support the deployment of the Nanox.ARC, an FDA-cleared, multisource digital tomosynthesis system that makes 3D imaging possible in more clinical settings at a lower cost and reduced radiation dose compared to traditional CT. U
PETACH TIKVA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended December 31, 2025, before market open on Monday, April 20, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 2025 Call The live webcast of the conference call may be accessed by using t
New regional partnership strengthens Nanox's presence and service support across outpatient imaging settings in Colorado, Wyoming and the western parts of Kansas and Nebraska Agreement aligns with Nanox's strategy to expand through regional distributors with strong commercial reach and service infrastructure PETACH TIKVA, Israel, April 2, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a new distribution agreement with Integrity Medical Service Inc., a Colorado based provider of imaging solutions serving hospitals, orthopedic practices, imaging cent
Live Leadership Updates
NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we
Live finance-specific insights
Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI Management to host conference call and webcast Monday, April 20, 2026 at 8:30 AM ET Appointed new CFO effective August 1, 2026 PETAH TIKVA, Israel, April 20, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2025, and provided a business update. Recent Highlights: Generated $3.7 million in revenue in the fourth quarter of 2025, compared to $3.0 million in the fourth quarter o
PETACH TIKVA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended December 31, 2025, before market open on Monday, April 20, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 2025 Call The live webcast of the conference call may be accessed by using t
Management to host conference call and webcast Thursday, November 20, 2025, at 8:30 AM ET Company advances commercialization and is on track to meet year-end system deployment target PETAH TIKVA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2025, and provided a business update. Recent Highlights: Generated $3.4 million in revenue in the third quarter of 2025, compared to $3.0 million in the third quarter of 2024.Acquired 100% of the stock of Vaso Healthcare IT, a provider of healthcare information technologies solu
PETACH TIKVA, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2025, before market open on Thursday, November 20, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q3 2025 Conference Call. The live webcast of the conference call may be ac
Management to host conference call and webcast Tuesday, August 12, 2025 at 8:30 AM ET Company continued to grow Nanox.ARC installed base and is on track to meet its year-end system deployment target PETAH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2025 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the second quarter of 2025, compared to $2.7 million in the second quarter of 2024.Grew Nanox.ARC system sales funnel exponentially in the quarter.The Company notified the FD
PETACH TIKVA, Israel, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2025, before market open on Tuesday, August 12, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q2 2025 Conference Call. The live webcast of the conference call may be accessed by
PETACH TIKVA, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the first quarter ended March 31, 2025, and provided a business update. Recent Highlights: Generated $2.8 million in revenue in the first quarter of 2025, compared to $2.6 million in the first quarter of 2024.Received 510(k) clearance from the FDA for the Nanox.ARC X, its updated multi-source digital Tomosynthesis system.Signed multiple commercial agreements to market the Nanox.ARC and the Nanox.AI solutions. "Since the beginning of 2025, Nanox has made consistent progress marketing our full end-
PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2025, before market open on Thursday, May 22, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2025 Earnings Call Registration. The live webcast of the conference call may be
PETACH TIKVA, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2024, before market open on Monday, March 31, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration. The live webcast of the conferenc
Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a key component of global strategic growth plan Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET PETACH TIKVA, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) -- November 21, 2024 — NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2024 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the third quarter of 2024, compared to $2.5 million in the third quarter of 2023
This live feed shows all institutional transactions in real time.
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)